CX-4945 sodium salt is primarily used as a potent and selective inhibitor of casein kinase 2 (CK2), a serine/threonine kinase that is overexpressed in various cancers. Its main application lies in oncology research, where it demonstrates antitumor activity by inducing apoptosis and inhibiting proliferation in cancer cells. It has shown promising results in preclinical studies against multiple myeloma, leukemia, and solid tumors such as glioblastoma and prostate cancer. CX-4945 sodium salt also enhances the efficacy of other anticancer therapies, including radiation and chemotherapy, by sensitizing resistant cancer cells. Due to its ability to cross the blood-brain barrier, it is being explored for treating brain tumors. Additionally, it has research applications in studying CK2-dependent signaling pathways involved in cell growth, inflammation, and viral infection.